-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
OBJECTIVE: To assess the association between detectable antibody responses to COVID-19 vaccination and factors such as B -cell depletion in patients receiving rituximab (RTX.
OBJECTIVE: To assess the association between detectable antibody responses to COVID-19 COVID-19 vaccination and factors such as B -cell depletion in patients receiving rituximab (RTX) therap.
Methods: We performed a retrospective review of cases of adult patients who received RTX and completed SARS-CoV-2 messenger RNA vaccinati.
RESULTS: Among the 56 patients treated with RTX , a significant difference in the level of B cell reconstitution was observed in seropositive patients compared with vaccinated seronegative patients (the proportion of B cells in total lymphocyte.
Conclusions: B -cell reconstitution and longer time since the patient's last exposure to RTX were associated with positive serological responses to the COVID-19 vaccin.
Source: Jinich,.
Jinich,.
, Schultz,.
, Jannat-Khah,.
and Spiera,.
(2022), B Cell Reconstitution Is Strongly Associated With COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Who Received Treatment With Rituxim.
Arthritis Rheumatol, 74: 776-78https://d.
org/11002/a.
42034 https://d.
org/11002/a.
42034Comment here